Related Experiment Video
Updated: May 30, 2026
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients
Takayuki Takimoto1, Tasuku Nakabori, Akio Osa
1Department of Internal Medicine, Toyonaka Municipal Hospital, 4-14-1 Shibahara-cho, Toyonaka, Osaka, 560-8565, Japan. taka2003@chp.toyonaka.osaka.jp
Abstract:
Renal dysfunction is a characteristic of many patients with cancer; however, a standard therapy has not been established for stage III or IV non-small-cell lung cancer (NSCLC) complicated with chronic renal failure. Docetaxel has a proven significant activity against NSCLC. This agent is predominantly eliminated by hepatobiliary extraction and is safe in patients with renal failure, including dialysis patients. Docetaxel is, thus, a therapeutic option in that patient population. Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. Little is known about tubular nephrotoxicity induced by docetaxel; however, oncologists should be aware of its possibility.
Insights
Docetaxel is a viable treatment for non-small-cell lung cancer (NSCLC) patients with renal failure. However, this chemotherapy can cause acute tubular nephrotoxicity, even in patients with normal kidney function.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Advanced non-small-cell lung cancer (NSCLC) frequently presents with renal dysfunction, complicating treatment choices.
- Established therapies for stage III-IV NSCLC with chronic renal failure are lacking.
- Docetaxel, a chemotherapy agent, shows significant activity against NSCLC and is primarily cleared hepatically, making it a potential option for patients with impaired renal function.
Observation:
- This study reports cases of acute tubular nephrotoxicity in NSCLC patients treated with docetaxel.
- Nephrotoxicity was observed even in patients with previously normal renal function.
- The mechanism of docetaxel-induced tubular damage is not well understood.
Findings:
- Docetaxel, while effective for NSCLC, carries a risk of causing acute tubular nephrotoxicity.
- This adverse renal effect can occur irrespective of the patient's baseline renal function.
- Oncologists must consider the potential for docetaxel-induced kidney damage.
Implications:
- Awareness of docetaxel-induced nephrotoxicity is crucial for oncologists managing NSCLC patients.
- Careful monitoring of renal function is recommended during docetaxel therapy.
- Further research is needed to elucidate the mechanisms and management of this adverse event.
